Nausicaa Clemente

Dr. Nausicaa Clemente

Department of Health Sciences (DiSS), University of Piemonte Orientale (UPO), Via Solaroli 17, 28100 Novara, Italy
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
LCLuigi Mario Castello
Luigi Mario Castello
Davide RaineriDavide Raineri
Davide Raineri
LSLivia Salmi
Livia Salmi
NCNausicaa Clemente
Nausicaa Clemente
RVRosanna Vaschetto
Rosanna Vaschetto
Annalisa ChiocchettiAnnalisa Chiocchetti
Annalisa Chiocchetti
Complex interactions between tumor and host cells regulate systemic tumor dissemination, a process that begins early at the primary tumor site and goes on until tumor cells detach themselves from the tumor mass and start migrating into the blood or lymphatic vessels. Metastatic cells colonize the target organs and are capable of surviving and growing at distant sites. In this context, osteopontin (OPN) appears to be a key determinant of the crosstalk between cancer cells and the host microenvironment, which in turn modulates immune evasion. OPN is overexpressed in several human carcinomas and has been implicated in inflammation, tumor progression, and metastasis. Thus, it represents one of the most attracting targets for cancer therapy. Within the tumor mass, OPN is secreted in various forms either by the tumor itself or by stroma cells, and it can exert either pro- or antitumorigenic effects according to the cell type and tumor microenvironment. Thus, targeting OPN for therapeutic purposes needs to take into account the heterogeneous functions of the multiple OPN forms with regard to cancer formation and progression. In this review, we will describe the role of systemic, tumor-derived, and stroma-derived OPN, highlighting its pivotal role at the crossroads of inflammation and tumor progression.

1 September 2014 in Vaccine
Verified
Journal Article
Closed access
Giuseppe CappellanoGiuseppe Cappellano
Giuseppe Cappellano
AWAbiy Demeke Woldetsadik
Abiy Demeke Woldetsadik
EOElisabetta Orilieri
Elisabetta Orilieri
YSYogesh Shivakumar
Yogesh Shivakumar
MRManuela Rizzi
Manuela Rizzi
UDUmberto Dianzani
Umberto Dianzani

20 December 2016 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
NCNausicaa Clemente
Nausicaa Clemente
Davide RaineriDavide Raineri
Davide Raineri
Giuseppe CappellanoGiuseppe Cappellano
Giuseppe Cappellano
Elena BoggioElena Boggio
Elena Boggio
FFFrancesco Favero
Francesco Favero
Annalisa ChiocchettiAnnalisa Chiocchetti
Annalisa Chiocchetti
Osteopontin (OPN) regulates the immune response at multiple levels. Physiologically, it regulates the host response to infections by driving T helper (Th) polarization and acting on both innate and adaptive immunity; pathologically, it contributes to the development of immune-mediated and inflammatory diseases. In some cases, the mechanisms of these effects have been described, but many aspects of the OPN function remain elusive. This is in part ascribable to the fact that OPN is a complex molecule with several posttranslational modifications and it may act as either an immobilized protein of the extracellular matrix or a soluble cytokine or an intracytoplasmic molecule by binding to a wide variety of molecules including crystals of calcium phosphate, several cell surface receptors, and intracytoplasmic molecules. This review describes the OPN structure, isoforms, and functions and its role in regulating the crosstalk between innate and adaptive immunity in autoimmune diseases.

9 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Monica ArgenzianoMonica Argenziano
Monica Argenziano
Casimiro Luca GigliottiCasimiro Luca Gigliotti
Casimiro Luca Gigliotti
NCNausicaa Clemente
Nausicaa Clemente
Elena BoggioElena Boggio
Elena Boggio
BFBenedetta Ferrara
Benedetta Ferrara
CDChiara Dianzani
Chiara Dianzani
Doxorubicin (DOX) is an anthracycline widely used in cancer therapy and in particular in breast cancer treatment. The treatment with DOX appears successful, but it is limited by a severe cardiotoxicity. This work evaluated the in vitro and in vivo anticancer effect of a new formulation of β-cyclodextrin nanosponges containing DOX (BNS-DOX). The BNS-DOX effectiveness was evaluated in human and mouse breast cancer cell lines in vitro in terms of effect on cell growth, cell cycle distribution, and apoptosis induction; and in vivo in BALB-neuT mice developing spontaneous breast cancer in terms of biodistribution, cancer growth inhibition, and heart toxicity. BNS-DOX significantly inhibited cancer cell proliferation, through the induction of apoptosis, with higher efficiency than free DOX. The breast cancer growth in BALB-neuT mice was inhibited by 60% by a BNS-DOX dose five times lower than the DOX therapeutic dose, with substantial reduction of tumor neoangiogenesis and lymphangiogenesis. Biodistribution after BNS-DOX treatment revealed a high accumulation of DOX in the tumor site and a low accumulation in the hearts of mice. Results indicated that use of BNS may be an efficient strategy to deliver DOX in the treatment of breast cancer, since it improves the anti-cancer effectiveness and reduces cardiotoxicity.

Verified
Journal Article
Open access
PDF file
NCNausicaa Clemente
Nausicaa Clemente
BFBenedetta Ferrara
Benedetta Ferrara
Casimiro Luca GigliottiCasimiro Luca Gigliotti
Casimiro Luca Gigliotti
Elena BoggioElena Boggio
Elena Boggio
MCMaria Teresa Capucchio
Maria Teresa Capucchio
CDChiara Dianzani
Chiara Dianzani
Aim: To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma. Materials and Methods: SLN-TMZ was obtained through fatty acid coacervation. Its pharmacological effects were assessed and compared with free TMZ in in vitro and in vivo models of melanoma and glioblastoma. Results: Compared to the standard free TMZ, SLN-TMZ exerted larger effects, when cell proliferation of melanoma cells, and neoangiogeneis were evaluated. SLN-TMZ also inhibited growth and vascularization of B16-F10 melanoma in C57/BL6 mice, without apparent toxic effects. Conclusion: SLN could be a promising strategy for the delivery of TMZ, allowing an increased stability of the drug and thereby its employment in the treatment of aggressive malignacies.

26 October 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
Davide RaineriDavide Raineri
Davide Raineri
CDChiara Dianzani
Chiara Dianzani
Giuseppe CappellanoGiuseppe Cappellano
Giuseppe Cappellano
FMFederica Maione
Federica Maione
Gianluca BaldanziGianluca Baldanzi
Gianluca Baldanzi
ACAnnalisa Chiocchetti
Annalisa Chiocchetti
ICOSL/ICOS are costimulatory molecules pertaining to immune checkpoints; their binding transduces signals having anti-tumor activity. Osteopontin (OPN) is here identified as a ligand for ICOSL. OPN binds a different domain from that used by ICOS, and the binding induces a conformational change in OPN, exposing domains that are relevant for its functions. Here we show that in vitro, ICOSL triggering by OPN induces cell migration, while inhibiting anchorage-independent cell growth. The mouse 4T1 breast cancer model confirms these data. In vivo, OPN-triggering of ICOSL increases angiogenesis and tumor metastatization. The findings shed new light on ICOSL function and indicate that another partner beside ICOS may be involved; they also provide a rationale for developing alternative therapeutic approaches targeting this molecular trio.